TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03937635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT04865705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Tilelizumab 200mg d1 Q3W Albumin Paclitaxel 260mg/m2 d1 Carboplatin/Cisplatin 75mg/m2/AUC5 d1 every 3 weeks
Study: NCT00742677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nutritional support
Description: Given orally
Study: NCT03937635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06228911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid (triamcinolone)
Description: triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid (triamcinolone)
Description: triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions
Study: NCT00259129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
Study: NCT03281993

Intervention type: OTHER
Intervention: CPAP AT
Description: If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
Study: NCT01119937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: 50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: 18µg capsules for inhalation, delivered via HandiHaler®
Study: NCT04249609

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HCHO meals and exercise
Description: Exercise will be conducted after high carbohydrate dinner and prior to high carbohydrate breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHO meals and exercise
Description: Exercise will be conducted after high fat dinner and prior to high fat breakfast
Study: NCT04370483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Gievn PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00049127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT00742677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nutritional support
Description: Given orally
Study: NCT03471819

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum serotonin level
Description: blood sample will be obtained to evaluate serum level of serotonin

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum serotonin level
Description: blood sample will be obtained to evaluate serum level of serotonin
Study: NCT00049127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies
Study: NCT00679861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling Intervention
Description: A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counselling Intervention
Description: A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert-system intervention
Description: Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
Study: NCT00817661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 10000 IU Vitamin A or placebo per week

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10000 IU Vitamin A or placebo per week
Study: NCT01046474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle
Description: Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted.
Study: NCT06092658

Intervention type: OTHER
Intervention: No Intervention
Description: no intervention
Study: NCT00274924

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously or intravenous bolus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT00679861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert-system intervention
Description: Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
Study: NCT05026073

Intervention type: BEHAVIORAL
Intervention: Information about clinical risk factors for endometrial cancer and endometrial hyperplasia
Description: age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.
Study: NCT02736721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
Study: NCT01472263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
Study: NCT05026073

Intervention type: BEHAVIORAL
Intervention: Information about clinical risk factors for endometrial cancer and endometrial hyperplasia
Description: age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.

Intervention type: BEHAVIORAL
Intervention: Information about clinical risk factors for endometrial cancer and endometrial hyperplasia
Description: age, race, parity, body mass index, last menstrual period, menstrual cycle type, hypertension, type II diabetes, anovulation, polycystic ovary syndrome, indication for hysterectomy and smoking history. Other epidemiologic risk factors including tamoxifen exposure, history of breast cancer, current hormone therapy use, anticoagulant use, oral contraception use, family history of endometrial, breast or colon cancer.

Intervention type: PROCEDURE
Intervention: Blood and endometrial tissue sampling
Description: * All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation.
Study: NCT04343001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 150mg
Study: NCT00274924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT04294823

Intervention type: DIAGNOSTIC_TEST
Intervention: Helicobacter Pylori Diagnostic
Description: Helicobacter Test INFAI with standard test Meal (1g citric acid as test meal and 75 mg C\^13 urea)~+ The C\^13 UBT with the new test (REFEX). All patients will take Nexium mups (40 mg) orally once daily 30 min before breakfast from day 1 to 28.

Intervention type: DEVICE
Intervention: Vital signs measurments
Description: No description;

Intervention type: DIAGNOSTIC_TEST
Intervention: endoscopy
Description: Upper endoscopy where 6 biopsy samples will be obtained . Two biopsies will be taken from antrum and corpus for histology. The biopsies will be stained with Haematoxylin \& Eosin and Giemsa stains, and gastritis wilt be scored using the Updated Sydney System 12,13 Two biopsies will be taken from antrum and corpus for rapid urease test (RUT) and two biopsies will be taken from antrum and corpus for culture. All biopsy samples will be analysed in the local laboratory of the centre.

Intervention type: DRUG
Intervention: Nexium Pill
Description: patients will take Nexium mups 40 mg orally once daily, 30 min before breakfast Nexium mups 40 mg will be discontinued after Day 28.
Study: NCT02963324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Study: NCT01338389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CITICOLINE
Description: Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Oral administration of placebo:~Form: Powder for solution duration: 5 years
Study: NCT01697241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
Study: NCT02588508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm packs
Description: : The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perineal massage
Description: The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins.
Study: NCT05026073

Intervention type: PROCEDURE
Intervention: Blood and endometrial tissue sampling
Description: * All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation.

Intervention type: PROCEDURE
Intervention: Blood and endometrial tissue sampling
Description: * All women will undergo planned hysterectomy.~* Venous blood sample will be collected prior to surgery.~* Endometrial sampling via Pipelle device will be performed immediately prior to hysterectomy~* Endometrial biopsy from the hysterectomy specimen will be obtained under direct vision~The plasma and serum obtained from the blood samples will be analysed with ATR-FTIR and Raman spectroscopes. Spectra from both wet and dry specimens will be recorded.~All tissue samples retrieved will be placed in Phosphate Buffered Solution for transfer to the histopathology laboratory. Spectra will be collected from the fresh samples with ATR-FTIR and Raman spectroscopes. Spectral analyses will subsequently be repeated on dry samples post fixation and processing.~All tissue samples will undergo haematoxylin and eosin staining after spectral analysis for standard histopathological confirmation.

Intervention type: PROCEDURE
Intervention: Lymph node sampling
Description: Lymph nodes will be excised if recommended as part of the standard treatment for endometrial cancer.~Each node will be cut in half or in quarters, depending on size, to expose the core. Wet and dry spectral analysis will be performed, followed by staining for histopathological confirmation.
Study: NCT03394222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preoperative budesonide inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: preoperative normal saline inhalation
Study: NCT02327650

Intervention type: PROCEDURE
Intervention: The examinations for bones in joints of OA and RA patients
Study: NCT00363415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: 100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
Study: NCT00274924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT02782104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine Nasal Spray
Description: Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram \[mg\] or 84 mg for those \< 65 years; 28 mg, 56 mg or 84 mg for those \>= 65 years). Participants \>= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
Study: NCT00363415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
Study: NCT04343001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 150mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 80mg
Study: NCT00858793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)
Description: Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
Study: NCT02365454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Graft Placement (Nexus)
Description: The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system.
Study: NCT01948414

Intervention type: PROCEDURE
Group type: OTHER
Intervention: electroencephalography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: electroencephalography

Intervention type: PROCEDURE
Group type: OTHER
Intervention: electroencephalography

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)
Study: NCT00274924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV
Study: NCT02602678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supine then Prone position
Description: One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone then supine position
Description: One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
Study: NCT00170690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
Study: NCT02815280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX-101, 4% minocycline foam
Description: FMX-101, 4% minocycline foam applied topically once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle foam applied topically once daily for 12 weeks
Study: NCT01126671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental Vitamin D
Description: Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.